“Simultaneous initiation of finerenone and an SGLT2 inhibitor provides early and additive effects on urine albumin-to-creatinine ratio reduction that are statistically and clinically significant ...

These can occur in many cancer types, and 40–70% of patients with these types of solid tumors either do not respond to immune checkpoint inhibitors or develop resistance during treatment.

Please provide your email address to receive an email when new articles are posted on . PCSK9 inhibitors lower cholesterol and risk for heart disease, but barriers to access exist. A pharmacist ...

A novel, allosteric and highly potent USP1 inhibitor, LAE120 exhibits robust tumor inhibitory activity across various xenograft models Significantly accelerated the progress of drug discovery ...

Video content above is prompted by the following: The ASH abstract by Mansour and colleagues suggests that for patients who have been on BTK inhibitors for more than 2 years, discontinuing therapy ...

A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs with the potential to interrupt disease progression. A national study ...

Panelists discuss how decisions to switch between Bruton tyrosine kinase (BTK) inhibitors are driven by multiple factors including intolerable toxicities, development of resistance mutations ...

Fusions can also cause deactivation of the protein’s tyrosine kinase function. TRK inhibition prevents adenosine triphosphate, the energy storage molecule, from binding to the fusion protein, which ...

As you may know, there are four main types of enzyme inhibition: noncompetitive, uncompetitive, competitive, and mixed inhibition mechanisms. The similarity in their names makes it difficult and ...